Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient hydrocortisone (WHO ATC code: H02AB09)

Original title (German): Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Hydrocortison (ATC-Code nach WHO: H02AB09)

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

March 31, 2028
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient hydrocortisone (ATC code according to WHO: H02AB09)

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedJanuary 16, 2026
Procurement stageActive solicitation
Response dueMarch 31, 2028
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Brinzolamid und Brimonidin (ATC: S01EC24)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tacrolimus, ATC D11AH01
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Alfacalcidol, ATC A11CC03
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Sultamicillin (ATC J01CR04).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Abirateron in der Wirkstärke 500mg und der Packungsgröße 90St.
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Progesteron (ausschl. Dafo. WKA), ATC G03DA04 für die Zeit 01.02.26 - 31.01.28 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Allergenextrakt aus Baumpollen (ausschl. in der Dafo. Pumplösung), ATC V01AA05 f. d. Z. 01.01.25 - 31.12.26
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Bempedoinsäure + Ezetimib, (OBO) ATC C10BA10 für die Zeit 01.03.2025 - 28.02.2027

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.